Key facts
- Akamis Bio’s last known valuation is $145.3M (Jan 2023).
- It has raised $184.6M; the latest was Later Stage VC ($60.0M) in Dec 2024.
- Notable investors include Salica Investments, ARCH Venture Partners, Bristol-Myers Squibb, Revelation Partners, SR One Capital Management — 25 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 25 names
- ·Watchlist + deal alerts for Akamis Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Akamis Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Akamis Bio
Operator of a clinical-stage oncology company intended to develop cancer gene therapies. The company focuses on immunobiology treatments for solid tumors using the proprietary intravenously administered T-SIGn virus platform, enabling patients to get proper treatment who are suffering from cancer.
- Sector
- Healthcare
- HQ
- Abingdon, United Kingdom
- Founded
- 2006
- Employees
- 34
- Website
- akamisbio.com/
- Ownership
- Privately Held (backing)
Akamis Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Akamis Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Akamis Bio in its N-PORT filings yet. We sweep new filings monthly.